HEALTH

McNeil rebrands Advanced Imodium Multi-Symptom Relief

BY Michael Johnsen

FOR WASHINGTON, Pa. McNeil Consumer Healthcare on Thursday rebranded its Imodium Advanced Imodium Multi-Symptom Relief to better position the brand as the fastest anti-diarrheal medicine that also relieves symptoms of gas, cramps, bloating and pressure.

Imodium Multi-Symptom Relief combines loperamide hydrochloride with simethicone for relief of diarrhea, as well as the gas, cramps, bloating and pressure that nearly 65 percent of diarrhea sufferers can also experience. Loperamide HCl works in the small and large intestines by slowing the increased motility and reducing the increased secretion of fluid and electrolytes that occur with diarrhea. Simethicone acts in the stomach and intestines by altering the surface tension of gas and mucus bubbles, enabling them to group together. This action accelerates the passage of gas through the intestine.

Acute diarrhea is the second most commonly reported illness in the United States after respiratory infections. Diarrhea affects people of all ages, with the average adult suffering four bouts of acute diarrhea per year, and 22 million people reporting experiencing diarrhea at least once a month. Acute diarrhea also affects the travel plans of up to 10 million travelers each year.

Common causes of acute diarrhea include many medications, food intolerance, excessive caffeine or alcohol consumption and premenstrual syndrome.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Advertising council makes recommendations on Constellation Wines’ dietary claims

BY Michael Johnsen

NEW YORK The National Advertising Division of the Council of Better Business Bureaus on Tuesday determined that Constellation Wines U.S./PolyPhenolics provided reasonable support for certain performance claims made for the company’s dietary supplement MegaNatural-BP, but recommended the company discontinue certain claims to avoid consumer confusion.

NAD was concerned that that the claim “Provide relief with half the cost, half the dose,” did not clearly identify the object of the comparison and suggested that consumers with high blood pressure could replace prescribed medication with a supplement.

NAD recommended that the advertiser discontinue the claim, “Provide relief with half the cost, half the dose and half the time” but noted that the advertiser can continue to discuss the differences between MegaNatural-BP and the competing Antigen Converting Enzyme (ACE) inhibitors which take 4-6 weeks of regular supplementation to work.

NAD recommended that to avoid the potential for any consumer confusion, and consistent with the findings of the studies on which it relies, the advertiser clearly and conspicuously disclose that MegaNatural-BP could be used as a part of a lifestyle management program for people with prehypertension and metabolic syndrome, and clearly state that consumers should “Consult your doctor before taking MegaNatural-BP.” 

The company, in its advertiser’s statement, said it “understands NAD’s decision as written and appreciates your thorough and well-explained rationale.  Polyphenolics agrees to modify its advertising as recommended.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Congressman ask for review of Bayer aspirin heart health claims

BY Michael Johnsen

WASHINGTON Two Michigan democrats have singled out Bayer’s marketing of its Aspirin with Heart Advantage, a combination product that includes a dietary supplement, that appears to go against a Food and Drug Administration’s request not to advertise such products, said House of Representatives Energy and Commerce Chairman John Dingell, according to a Reuters report published Tuesday.

Dingell, along with Rep. Bart Stupak, fired off two letters suggesting that the supplement/analgesic combination product might need FDA approval—one to Bayer and the other to Health and Human Services secretary Michael Leavitt. HHS oversees the FDA.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?